SynthesisRheumatology (Oxford, England)2026
The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.
Synthesis in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmune thrombocytopenia (ITP) carries an increased thrombotic risk, especially when associated with autoimmune conditions and/or antiphospholipid antibody (aPL) positivity. The burden of thrombotic events in patients treated with second-line therapies in these instances has not been systematically studied.
methodsMedline and Embase were searched from 2010 to 16 November 2025, for studies on high-risk ITP patients receiving eligible second-line treatments, including thrombopoietin receptor agonists (TPO-RAs), fostamatinib, rituximab, other immune suppressants (ciclosporin, cyclophosphamide, azathioprine and mycophenolate) and splenectomy. High-risk ITP was defined as (i) primary ITP (pITP) with aPL positivity or (ii) secondary ITP (sITP) when associated to an autoimmune disease posing an increased thrombotic risk. The primary outcome was the frequency of any thrombotic event during follow-up. Secondary outcomes were the separate frequencies of arterial and venous thromboses, overall and stratified by treatment.
resultsWe included 13 studies providing data of 308 high-risk ITP patients on at least one eligible second-line treatment. Thrombosis occurred in 40 patients (10%, 95% CI 5-19) over a median follow-up ranging from 6 to 42 months. Stratifying by treatment, thrombosis occurred in 30 patients on TPO-RAs (16%, 95% CI 11-22), in 3 on rituximab (14%, 95% CI 3-35), in 3 on immune suppressants (11%, 95% CI 2-28) and in 6 who underwent splenectomy (12%, 95% CI 4-24).
conclusionWe have found a consistent thrombotic burden in high-risk ITP patients on second-line therapy, evident across all examined treatment options, underscoring the pro-thrombotic immune milieu of this population and the need for tailored risk-mitigation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.